Successful Public Offering: Eupraxia Pharmaceuticals closed a public offering of 14,636,363 common shares at $5.50 each, raising approximately $80.5 million to support the development of its drug EP-104GI and other clinical initiatives.
Use of Proceeds: The funds will primarily be used for advancing the product pipeline, including clinical trials, regulatory submissions, and expanding the company's intellectual property portfolio, with a focus on addressing significant unmet medical needs.
EPRX
$6.16+Infinity%1D
Analyst Views on EPRX
Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 11.55 USD with a low forecast of 10.89 USD and a high forecast of 11.88 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast EPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EPRX is 11.55 USD with a low forecast of 10.89 USD and a high forecast of 11.88 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.160
Low
10.89
Averages
11.55
High
11.88
Current: 6.160
Low
10.89
Averages
11.55
High
11.88
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$12
2025-08-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12
2025-08-20
maintain
Buy
Reason
H.C. Wainwright believes Celldex's (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive thesis on Eupraxia Pharmaceuticals (EPRX). Barzolvolimab did not show improvements in eosinophilic esophagitis symptoms or endoscopic measures of disease activity compared to placebo, the analyst tells investors in a research note. The firm says a potential competitor to Eupraxia in eosinophilic esophagitis has been removed. The barzolvolimab study also validates the "simpler but more effective approach" Eupraxia is taking with EP-104GI, contends H.C. Wainwright. The firm has a Buy rating on the shares with a $12 price target.
Cantor Fitzgerald
NULL -> Overweight
initiated
$11
2025-07-24
Reason
Cantor Fitzgerald
Price Target
$11
2025-07-24
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with an Overweight rating and $11 price target.
H.C. Wainwright
NULL -> Buy
initiated
$12
2025-06-26
Reason
H.C. Wainwright
Price Target
$12
2025-06-26
initiated
NULL -> Buy
Reason
Canaccord
Speculative Buy
initiated
$9
2025-06-17
Reason
Canaccord
Price Target
$9
2025-06-17
initiated
Speculative Buy
Reason
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
